rs3850641 — TNFSF4 TNFSF4 (OX40L) Intron 1 Variant

OX40 Ligand and the Immune Gate of Atherosclerosis

TNFSF4 encodes OX40 ligand (OX40L, also called CD252), a co-stimulatory molecule of the TNF superfamily that serves as the key amplifier of T-cell activation in inflammatory settings. OX40L is expressed on antigen-presenting cells — particularly macrophages, dendritic cells, and vascular endothelial cells — and engages OX40 on activated CD4+ T cells to extend their survival, promote cytokine secretion, and drive clonal expansion. Within atherosclerotic plaques, OX40L expression is markedly elevated compared to healthy vascular tissue, driven by oxidized LDL and other inflammatory mediators. The rs3850641 variant sits in the first intron of TNFSF4, in strong linkage disequilibrium with a promoter polymorphism (rs45454293) that regulates OX40L gene expression.

The Mechanism

The functional variant linked to rs3850641 is rs45454293¹¹ rs45454293
A promoter SNP in LD with rs3850641 at r²=0.70; the T-allele reduces TNFSF4 transcription by ~50% compared to the C-allele in luciferase reporter assays, attributed to binding of a transcriptional repressor. The rs3850641 SNP itself has no direct effect on promoter activity, but because both SNPs travel together on the same haplotype block — the TG haplotype combining rs45454293T and rs3850641G — the G allele at rs3850641 tags a state of reduced OX40L expression in vascular tissue.

Paradoxically, lower OX40L expression appears to increase cardiovascular risk. This may reflect an immunoregulatory role: OX40L signaling is also required for the proper differentiation and persistence of regulatory T cells (Tregs). Disruption of OX40L in the plaque microenvironment could impair Treg-mediated suppression of inflammatory effector T cells, allowing uncontrolled T-cell–driven inflammation to accelerate plaque growth and destabilization. Consistent with this, anti-OX40L antibody blockade in LDL receptor-deficient mice²² anti-OX40L antibody blockade in LDL receptor-deficient mice
Guo et al., Arterioscler Thromb Vasc Biol 2007 — anti-OX40L antibody reduced atherosclerotic lesion area by approximately 53% in Ldlr−/− mice by attenuating Th2-mediated responses and preserving anti-oxLDL IgM antibodies attenuated atherogenesis, pointing to the pathway as a therapeutic target rather than a simple risk amplifier.

Elevated soluble OX40L (sOX40L) in circulation — released primarily from activated platelets — correlates with acute coronary syndrome severity, plaque instability, and elevated matrix metalloproteinase (MMP-9, MMP-3) levels, reinforcing OX40L as a biomarker of active plaque inflammation.

The Evidence

The variant was first implicated by Wang et al. in Nature Genetics 2005³³ Wang et al. in Nature Genetics 2005
Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility, which used positional cloning from the murine atherosclerosis susceptibility locus Ath1 to identify TNFSF4 as a human candidate gene. The rs3850641 G allele was significantly more frequent in MI cases than controls in two independent Swedish cohorts. Subsequent work by Cunningham et al. PLoS ONE 2011⁴⁴ Cunningham et al. PLoS ONE 2011
A Common Polymorphism in the Promoter Region of the TNFSF4 Gene Is Associated with Lower Allele-Specific Expression and Risk of MI identified rs45454293 as the functional promoter variant in LD with rs3850641 (r²=0.70), with the TG haplotype significantly enriched in female MI patients vs controls in the SCARF cohort (P=0.01), and demonstrated 50% reduced OX40L promoter activity for the T-allele.

A Chinese Han case-control study (Li et al. Oncotarget 2018, PMID 29921578 — 454 cases, 512 controls)⁵⁵ (Li et al. Oncotarget 2018, PMID 29921578 — 454 cases, 512 controls) found that homozygous GG carriers had significantly elevated MI risk (crude OR 2.00, 95% CI 1.04–3.86, P=0.039; adjusted OR 2.29, 95% CI 1.20–4.69, P=0.023), while the AG heterozygous genotype conferred no significant independent risk under additive or dominant models.

However, larger meta-analyses show overall null results in aggregate populations. A meta-analysis of 9 studies (Fu et al. 2016, PMID 27008001)⁶⁶ meta-analysis of 9 studies (Fu et al. 2016, PMID 27008001) found allelic OR 1.10 (95% CI 0.96–1.27, P=0.174), and a systematic review of 11 studies covering 3,865 cases and 6,344 controls (Lu et al. 2018, PMID 29424751)⁷⁷ systematic review of 11 studies covering 3,865 cases and 6,344 controls (Lu et al. 2018, PMID 29424751) found OR 1.02 (95% CI 0.89–1.17) for the G allele — no overall association. These null findings likely reflect population stratification (original signal primarily in European women), heterogeneity across disease definitions (CHD vs. MI specifically), and statistical power limitations for the rare GG genotype (only ~2% of individuals).

The GG-specific risk signal (recessive model OR ~2) remains coherent across the positive studies and is mechanistically plausible; the overall null meta-analysis findings reflect the rarity of GG homozygotes diluting allele-level effects. Evidence is classified as moderate — replicated in multiple independent studies under the recessive model, with a plausible regulatory mechanism, but no established clinical guidelines and significant heterogeneity across populations.

Practical Actions

For GG homozygotes, the elevated MI risk under the recessive model (OR ~2) warrants proactive cardiovascular monitoring. The risk appears particularly pronounced in women and in populations of East Asian and South Asian descent where OX40L pathway activity in the context of this haplotype may interact differently with other risk factors. Tracking inflammatory biomarkers such as hs-CRP and sOX40L alongside standard lipid panels provides the most relevant picture of vascular inflammatory burden for this genotype.

Interactions

rs3850641 is in linkage disequilibrium with the functional promoter SNP rs45454293 (r²=0.70); the TG haplotype combining both minor alleles carries the highest risk signal in women. rs2205960 and other upstream TNFSF4 promoter region SNPs (rs10912580, rs12039904, rs1234317) form a distinct haplotype block associated with systemic lupus erythematosus susceptibility, illustrating that TNFSF4 haplotypes have different disease consequences depending on which part of the regulatory region they tag.

Individuals carrying both rs3850641 GG and cardiovascular-risk variants in classical inflammatory pathways (e.g., IL-6 signaling genes, CRP variants) may have compounded atherosclerotic risk through synergistic immune activation in the vascular wall — an interaction that has not been formally studied but is mechanistically plausible given the T-cell co-stimulatory nature of the OX40L pathway.